ALK and non-small cell lung carcinoma: Similarly, a prospective study on 282 previously untreated NSCLC patients showed non-inferior sensitivity of ctDNA analysis compared to tissue genotyping in identifying actionable targets, including ALK fusions (NILE study, Non-invasive versus Invasive Lung Evaluation; ClinicalTrials.gov; NCT03615443).